Cellegesic nitroglycerin: Phase III started

PSK began the placebo-controlled, U.S. Phase III APT trial in 246 patients. The company markets the agent as Rectogesic in the U.K., Australia, New Zealand and South Korea. PSK licensed worldwide rig...